GlobalData on MSN

ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA

If the Phase III trials of the oral GLP-1RA are successful, AstraZeneca is set to join a fast-growing market.

AstraZeneca's obesity drug shows promise as analysts see upside beyond consensus

AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental ...

AstraZeneca’s GLP-1 Pill Clears Early Hurdle in Diabetes, Obesity Tests

AstraZeneca’s experimental GLP-1 pill cut body weight by nearly 12% in obese patients over 36 weeks and reduced A1C, a metric ...
Business Wire

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month ...

AstraZeneca commits $50 billion to expand U.S. research, manufacturing and patient access to new medicines

Food and Drug Administration on Tuesday said it added ‌bemotrizinol to its list of permitted active ‌ingredients, marking the ...

AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial

By Maggie Fick LONDON, June 8 (Reuters) - AstraZeneca said on Monday that patients lost 10.5% of their body weight after 26 ...
FiercePharma

One look: AstraZeneca unifies patient-physician messaging for asthma blockbuster Fasenra

AstraZeneca is refreshing its Fasenra campaign. Almost six years into the launch, the Big Pharma has established consistent messaging across physicians and patients for the first time, tying the brand ...
The Business Journals

AstraZeneca capping patients' monthly out-of-pocket expenses for inhaled medicines at $35

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The AstraZeneca patient spending ...
Business Wire

AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of ...
AOL

AstraZeneca to cut some direct-to-patient US drug prices after Trump demand

LONDON (Reuters) -AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying U.S. patients at a discount of up to 70% off list prices, the latest pharma company to do ...